GNMK - ゲンマ―ク・ダイアグノシス (GenMark Diagnostics Inc.) ゲンマ―ク・ダイアグノシス

 GNMKのチャート


 GNMKの企業情報

symbol GNMK
会社名 GenMark Diagnostics Inc. (ゲンマ―ク・ダイアグノシス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 ゲンマーク・ダイアグノスティクス(GenMark Diagnostics Inc.)は分子診断会社である。同社は複雑医学的状態の診断に役立つマルチプレックス分子検査の開発と商品化に従事する。同社はeSensor電気化学検出技術に基づくマルチプレックス分子試験を開発・商品化する。同社はXT-8機器で実行される4つの食品医薬品局(FDA)除外診断テスト、呼吸器ウイルスパネル、嚢胞性線維症のジェノタイピング試験、ワルファリン感受性試験及び血栓症リスク試験を提供する。同社はまた、C型肝炎(HCV)ジェノタイピング試験及び関連カスタム製造試薬、2C19ジェノタイピング試験を提供する。そのバージョンは研究専用(RUO)XT-8機器に使用できる。XT-8とePlexテスト・カートリッジは個別の電極と複数のシグナル・プローブの組み合わせを利用して、単一サンプルから数十種類のターゲット・バイオマーカーを検出することにより、多重化テストを可能にする。   ゲンマ―ク・ダイアグノシスは、米国の分子診断会社。「XT-8システム」は、独自の電気化学的検出技術を採用しタッチスクリ―ンコンピュ―タ―とアナライザ・ベンチトップ・ワ―クステ―ションで構成される。嚢胞性線維症ジェノタイピング・テスト、ワルファリン感受性試験、血栓リスク試験、呼吸器ウイルス・パネル・テストなどを展開する。   
本社所在地 5964 La Place Court Carlsbad CA 92008-8829 USA
代表者氏名 James Charles Fox ジェームスチャールズフォックス
代表者役職名 Independent Chairman of the Board
電話番号 +1 760-448-4300
設立年月日 40210
市場名 NASDAQ National Market System
ipoyear 2010年
従業員数 517人
url www.genmarkdx.com
nasdaq_url https://www.nasdaq.com/symbol/gnmk
adr_tso
EBITDA EBITDA(百万ドル) -48.91600
終値(lastsale) 6.275
時価総額(marketcap) 349850432.675
時価総額 時価総額(百万ドル) 325.59780
売上高 売上高(百万ドル) 63.21100
企業価値(EV) 企業価値(EV)(百万ドル) 298.93680
当期純利益 当期純利益(百万ドル) -57.89000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 GenMark Diagnostics Inc revenues increased 43% to $35.6M. Net loss decreased 12% to $27.9M. Revenues reflect License and other revenue increase of 8% to $143K. Lower net loss reflects Research and development decrease of 34% to $15.9M (expense) Interest Income increase from $106K to $389K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.67 to -$0.50.

 GNMKのテクニカル分析


 GNMKのニュース

   GenMark Diagnostics Inc Shares Approach 52-Week High - Market Mover  2021/04/13 22:30:00 Kwhen Finance
GenMark Diagnostics Inc shares closed today at 1.1% below its 52 week high of $24.25, giving the company a market cap of $1B. The stock is currently up 64.3% year-to-date, up 251.8% over the past 12 months, and up 328.4% over the past five years. This week, the Dow Jones Industrial Average rose 0.9%, and the S&P 500 rose 1.2%. Trading Activity Trading volume this week was 6.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 367.3% The company's stock price performance over the past 12 months beats the peer average by 384.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   GenMark Diagnostics Inc Shares Close in on 52-Week High - Market Mover  2021/04/08 22:30:00 Kwhen Finance
GenMark Diagnostics Inc shares closed today at 1.5% below its 52 week high of $24.25, giving the company a market cap of $1B. The stock is currently up 64.3% year-to-date, up 291.4% over the past 12 months, and up 356.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.9%, and the S&P 500 rose 2.7%. Trading Activity Trading volume this week was 82.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 654.4% The company's stock price performance over the past 12 months beats the peer average by 500.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   GenMark Diagnostics Inc Shares Close in on 52-Week High - Market Mover  2021/04/07 22:30:00 Kwhen Finance
GenMark Diagnostics Inc shares closed today at 1.1% below its 52 week high of $24.25, giving the company a market cap of $1B. The stock is currently up 64.3% year-to-date, up 291.4% over the past 12 months, and up 328.4% over the past five years. This week, the Dow Jones Industrial Average rose 1.9%, and the S&P 500 rose 2.7%. Trading Activity Trading volume this week was 72.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 654.4% The company's stock price performance over the past 12 months beats the peer average by 500.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   GenMark Diagnostics Inc. Shares Near 52-Week High - Market Mover  2021/03/24 22:30:00 Kwhen Finance
GenMark Diagnostics Inc. shares closed today at 0.4% below its 52 week high of $24.25, giving the company a market cap of $1B. The stock is currently up 65.5% year-to-date, up 487.8% over the past 12 months, and up 384.2% over the past five years. This week, the Dow Jones Industrial Average rose 1.4%, and the S&P 500 rose 1.7%. Trading Activity Trading volume this week was 14.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 1009.2% The company's stock price performance over the past 12 months beats the peer average by 782.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   GenMark Diagnostics Inc. Shares Approach 52-Week High - Market Mover  2021/03/22 22:30:00 Kwhen Finance
GenMark Diagnostics Inc. shares closed today at 0.7% below its 52 week high of $24.17, giving the company a market cap of $1B. The stock is currently up 64.3% year-to-date, up 465.8% over the past 12 months, and up 386.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.7%, and the S&P 500 fell 0.6%. Trading Activity Trading volume this week was 41.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 962.4% The company's stock price performance over the past 12 months beats the peer average by 526.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   COVID-19 Detection Kits Market | Co-Diagnostics, Inc F. Hoffmann-La Roche AG, Siemens Healthineers AG, Thermo Fisher Scientific, Abbott Laboratories, BGI, Cepheid Inc, BioFire Diagnostics, GenMark Diagnostics  2021/03/23 05:19:10 OpenPR
COVID-19 Detection Kits Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading players
   GENMARK INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GenMark Diagnostics - GNMK  2021/03/17 18:02:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of GenMark Diagnostics (NasdaqGM: GNMK) to F. Hoffmann-La Roche Ltd. Under the terms of the proposed transaction, shareholders of GenMark will receive only $24.05 in cash for each share of GenMark that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or
   3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy  2021/03/16 11:41:00 Benzinga
Roche Holding AG (OTC: RHHBY) acquired GenMark Diagnostics, Inc (NASDAQ: GNMK) in a $1.8 billion deal on Monday, the same day Veracyte …
   Roche, ABD’li rakibi GenMark’ı satın aldı  2021/03/16 11:14:00 Dünya Gazetesi
Roche, ABD merkezli GenMark Diagnostics'i 1.8 milyar dolara satın alarak portföyündeki test boşluğunu doldurdu.
   Stocks making the biggest moves in the premarket: GenMark Diagnostics, AMC Entertainment, Eli Lilly & more - We Beat the Broker  2021/03/15 19:00:00 We Beat the Broker
Take a look at some of the biggest movers in the premarket: GenMark Diagnostics (GNMK) – GenMark will be bought by Swiss drugmaker Roche for $1.8 billion
   COVID-19 Detection Kits Market | Co-Diagnostics, Inc F. Hoffmann-La Roche AG, Siemens Healthineers AG, Thermo Fisher Scientific, Abbott Laboratories, BGI, Cepheid Inc, BioFire Diagnostics, GenMark Diagnostics  2021/03/23 05:19:10 OpenPR
COVID-19 Detection Kits Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading players
   GENMARK INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GenMark Diagnostics - GNMK  2021/03/17 18:02:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of GenMark Diagnostics (NasdaqGM: GNMK) to F. Hoffmann-La Roche Ltd. Under the terms of the proposed transaction, shareholders of GenMark will receive only $24.05 in cash for each share of GenMark that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or
   3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy  2021/03/16 11:41:00 Benzinga
Roche Holding AG (OTC: RHHBY) acquired GenMark Diagnostics, Inc (NASDAQ: GNMK) in a $1.8 billion deal on Monday, the same day Veracyte …
   Roche, ABD’li rakibi GenMark’ı satın aldı  2021/03/16 11:14:00 Dünya Gazetesi
Roche, ABD merkezli GenMark Diagnostics'i 1.8 milyar dolara satın alarak portföyündeki test boşluğunu doldurdu.
   Stocks making the biggest moves in the premarket: GenMark Diagnostics, AMC Entertainment, Eli Lilly & more - We Beat the Broker  2021/03/15 19:00:00 We Beat the Broker
Take a look at some of the biggest movers in the premarket: GenMark Diagnostics (GNMK) – GenMark will be bought by Swiss drugmaker Roche for $1.8 billion

 関連キーワード  (先端医療機器_テクノロジ― 米国株 ゲンマ―ク・ダイアグノシス GNMK GenMark Diagnostics Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)